What is NDC 67919-030?

67919-030 is the product NDC for Zerbaxa, Ceftolozane sulfate 1 g/10mL; Tazobactam sodium .5 g/10mL injection, powder, lyophilized, for solution, listed with the FDA by Merck Sharp & Dohme LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Ceftolozane sulfate, Tazobactam sodium.

Merck Sharp & Dohme LLC, NDC labeler code 67919. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Zerbaxa?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Zerbaxa NDC 67919-030 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)67919-030Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67919-0030Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67919-030-01	67919003001	10 VIAL, SINGLE-DOSE in 1 CARTON (67919-030-01) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Dec 19, 2014

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Zerbaxa
Generic name (nonproprietary): ceftolozane and tazobactam
Active ingredients: Ceftolozane sulfate — 1 g/10mLTazobactam sodium — .5 g/10mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Merck Sharp & Dohme LLCNDC labeler code 67919
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 206829
Marketing start: Dec 19, 2014
Listing expires: Dec 31, 2027
Other FDA classes: Cephalosporins (Chemical structure)beta Lactamase Inhibitors (Mechanism)
Identifiers: Product ID 67919-030_23d9b7be-abf3-4ca6-bce8-d80643a708e7SPL ID 23d9b7be-abf3-4ca6-bce8-d80643a708e7SPL set ID 70ac1d90-eff3-4f0b-9f46-5846c571b32fRxCUI 1597615, 1597620UNII 7R247U84HY, UXA545ABTT
Pharmacologic class: Cephalosporin Antibacterial; beta Lactamase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N467919003001 followed by a unit qualifier and the quantity

Package 67919-0030-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 12, 2026.

Indications (excerpt from the label)

ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms in adult and pediatric patients (at least 32 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole. ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis. ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP). ( 1.3 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bact…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 67919-030

What is NDC 67919-030?: 67919-030 is the product NDC for Zerbaxa, Ceftolozane sulfate 1 g/10mL; Tazobactam sodium .5 g/10mL injection, powder, lyophilized, for solution, listed with the FDA by Merck Sharp & Dohme LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Zerbaxa (Ceftolozane and tazobactam).
What is the active ingredient?: Ceftolozane sulfate, Tazobactam sodium.
Who is the labeler?: Merck Sharp & Dohme LLC, NDC labeler code 67919. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Zerbaxa?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Zerbaxa (Ceftolozane and tazobactam) NDC 67919-030